Breaking Finance News

NewLink Genetics (NASDAQ:NLNK) target price raised to $22.00, reported today by BofA Merrill

NewLink Genetics (NASDAQ:NLNK) had its target price raised to $22.00 by BofA Merrill in a report released 10/13/2017. The new target price indicates a possible upside of 0.96% based on the company's last stock close price.

Previously on 9/11/2017, Stifel reported on NewLink Genetics (NASDAQ:NLNK) increased the target price from $14.00 to $29.00. At the time, this indicated a possible upside of 0.64%.

Yesterday NewLink Genetics (NASDAQ:NLNK) traded 1.16% higher at $11.25. The company’s 50-day moving average is $10.67 and its 200-day moving average is $11.52. The last closing price is down -1.24% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the same time period. 1,695,102 shares of the stock traded hands, down from an average trading volume of 2,542,700

Performance Chart

NewLink Genetics (NASDAQ:NLNK)

With a total market value of $0, NewLink Genetics has with a one year low of $5.90 and a one year high of $25.17 .

A total of 6 equity analysts have released a ratings update on NLNK. Two equity analysts rating the company a strong buy, three equity analysts rating the company a buy, one equity analyst rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $34.33.

Brief Synopsis About NewLink Genetics (NASDAQ:NLNK)

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company's portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system's tolerance to cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.